191 related articles for article (PubMed ID: 34257552)
1. Loss of ARID1A Expression as a Favorable Prognostic Factor in Early-Stage Grade 3 Endometrioid Endometrial Carcinoma Patients.
Kato MK; Yoshida H; Tanase Y; Uno M; Ishikawa M; Kato T
Pathol Oncol Res; 2021; 27():598550. PubMed ID: 34257552
[No Abstract] [Full Text] [Related]
2. Unique prognostic features of grade 3 endometrioid endometrial carcinoma: Findings from 101 consecutive cases at a Japanese tertiary cancer center.
Kato MK; Yoshida H; Uehara T; Uno M; Ishikawa M; Miyasaka N; Kato T
Taiwan J Obstet Gynecol; 2021 Mar; 60(2):238-244. PubMed ID: 33678322
[TBL] [Abstract][Full Text] [Related]
3. Mismatch repair deficiency identifies patients with high-intermediate-risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: A prognostic biomarker.
Backes FJ; Haag J; Cosgrove CM; Suarez A; Cohn DE; Goodfellow PJ
Cancer; 2019 Feb; 125(3):398-405. PubMed ID: 30561762
[TBL] [Abstract][Full Text] [Related]
4. Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups.
Bosse T; Nout RA; McAlpine JN; McConechy MK; Britton H; Hussein YR; Gonzalez C; Ganesan R; Steele JC; Harrison BT; Oliva E; Vidal A; Matias-Guiu X; Abu-Rustum NR; Levine DA; Gilks CB; Soslow RA
Am J Surg Pathol; 2018 May; 42(5):561-568. PubMed ID: 29505428
[TBL] [Abstract][Full Text] [Related]
5. ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas.
Allo G; Bernardini MQ; Wu RC; Shih IeM; Kalloger S; Pollett A; Gilks CB; Clarke BA
Mod Pathol; 2014 Feb; 27(2):255-61. PubMed ID: 23887303
[TBL] [Abstract][Full Text] [Related]
6. [Expression and significance of immune checkpoint B7-homolog 4 in endometrial cancer].
Zong LJ; Xiang Y; Yu SN; Lu ZH; Chen J; Huang WH
Zhonghua Fu Chan Ke Za Zhi; 2022 Dec; 57(12):921-931. PubMed ID: 36562226
[No Abstract] [Full Text] [Related]
7. Clinicopathologic characteristics and outcomes of endometrial Cancer patients with mismatch repair deficiency in the era of universal Lynch syndrome screening.
Carr C; Son J; Yao M; Priyadarshini A; Marquard J; Vargas R; Michener C; AlHilli MM
Gynecol Oncol; 2020 Dec; 159(3):712-720. PubMed ID: 33046272
[TBL] [Abstract][Full Text] [Related]
8. ARID1 and BRG1 Expression in Endometrial Cancer.
Kontomanolis EN; Symeonidis P; Nikolettos K; Perros P; Rody A; Tsikouras P; Nikolettos N; Giatromanolaki A
In Vivo; 2024; 38(3):1260-1265. PubMed ID: 38688602
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical study of endometrial high-grade endometrioid carcinoma with or without a concurrent low-grade component: implications for pathogenetic and survival differences.
Mao TL; Ayhan A; Kuo KT; Lin MC; Tseng LH; Ogawa H
Histopathology; 2015 Oct; 67(4):474-82. PubMed ID: 25648330
[TBL] [Abstract][Full Text] [Related]
10. ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas.
Werner HM; Berg A; Wik E; Birkeland E; Krakstad C; Kusonmano K; Petersen K; Kalland KH; Oyan AM; Akslen LA; Trovik J; Salvesen HB
Mod Pathol; 2013 Mar; 26(3):428-34. PubMed ID: 23080032
[TBL] [Abstract][Full Text] [Related]
11. The ARID1A, p53 and ß-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium.
Heckl M; Schmoeckel E; Hertlein L; Rottmann M; Jeschke U; Mayr D
PLoS One; 2018; 13(2):e0192881. PubMed ID: 29451900
[TBL] [Abstract][Full Text] [Related]
12. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level.
Alkushi A; Lim P; Coldman A; Huntsman D; Miller D; Gilks CB
Int J Gynecol Pathol; 2004 Apr; 23(2):129-37. PubMed ID: 15084841
[TBL] [Abstract][Full Text] [Related]
13. The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification.
Guan J; Xie L; Luo X; Yang B; Zhang H; Zhu Q; Chen X
J Gynecol Oncol; 2019 Jan; 30(1):e13. PubMed ID: 30479097
[TBL] [Abstract][Full Text] [Related]
14. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
Alvarez T; Miller E; Duska L; Oliva E
Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and Clinicopathological Significance of ARID1A in Endometrium-Related Gynecological Cancers: A Meta-Analysis.
Liu G; Xu P; Fu Z; Hua X; Liu X; Li W; Zhang M; Wu J; Wen J; Xu J; Jia X
J Cell Biochem; 2017 Dec; 118(12):4517-4525. PubMed ID: 28466574
[TBL] [Abstract][Full Text] [Related]
16. Is Older Age a Real Adverse Prognostic Factor in Women With Early-Stage Endometrial Carcinoma? A Matched Analysis.
Haley L; Burmeister C; Buekers T; Elshaikh MA
Int J Gynecol Cancer; 2017 Mar; 27(3):479-485. PubMed ID: 28060139
[TBL] [Abstract][Full Text] [Related]
17. DNA mismatch repair deficiency and p53 abnormality are age-related events in mixed endometrial carcinoma with a clear cell component.
Ida N; Nakamura K; Saijo M; Nasu A; Yoshino T; Masuyama H; Yanai H
Pathol Res Pract; 2021 Apr; 220():153383. PubMed ID: 33676104
[TBL] [Abstract][Full Text] [Related]
18. Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer.
Reijnen C; Küsters-Vandevelde HVN; Prinsen CF; Massuger LFAG; Snijders MPML; Kommoss S; Brucker SY; Kwon JS; McAlpine JN; Pijnenborg JMA
Gynecol Oncol; 2019 Jul; 154(1):124-130. PubMed ID: 31103324
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors of synchronous endometrial and ovarian endometrioid carcinoma.
Yoneoka Y; Yoshida H; Ishikawa M; Shimizu H; Uehara T; Murakami T; Kato T
J Gynecol Oncol; 2019 Jan; 30(1):e7. PubMed ID: 30479091
[TBL] [Abstract][Full Text] [Related]
20. [Clinicopathologic and survival analysis of synchronous primary endometrial and ovarian cancer].
Wang Y; Yu M; Yang JX; Cao DY; Zhang Y; Shen K; You Y
Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):816-822. PubMed ID: 30585019
[No Abstract] [Full Text] [Related]
[Next] [New Search]
